Please login to the form below

Not currently logged in
Email:
Password:

cediranib

This page shows the latest cediranib news and features for those working in and with pharma, biotech and healthcare.

AZ withdraws EU filing for ovarian cancer drug cediranib

AZ withdraws EU filing for ovarian cancer drug cediranib

AZ withdraws EU filing for ovarian cancer drug cediranib. Maintains cediranib’ s value as a combination therapy despite EMA information request. ... While its role as a monotherapy is ended, cediranib remains an important component of AZ's combination

Latest news

  • ASCO: AZ’s ovarian cancer combination aces trial ASCO: AZ’s ovarian cancer combination aces trial

    ASCO: AZ’ s ovarian cancer combination aces trial. Olaparib/cediranib combo demonstrates progression-free survival of 17.7 months. ... Combining olaparib and cediranib may herald the beginning of treatments that avoid chemotherapy in some patients with

  • Glioblastomas - a personalised future? Glioblastomas - a personalised future?

    Many agents have been unsuccessful. One of these, the pan-VEGF inhibitor cediranib, was discontinued at phase 3 due to disappointing results from pivotal studies.

  • Extending the arsenal

    It is also only one of a handful of therapies — along with aflibercept (Regeneron Pharmaceuticals), brivanib alaninate (Bristol-Myers Squibb) and cediranib (AstraZeneca) — in late-stage clinical trials for this type

  • AZ's Recentin trial disappoints

    AZ's Recentin trial disappoints. AstraZeneca's colorectal cancer drug, Recentin (cediranib), has failed to match Roche's Avastin (bevacizumab) in a phase II/III comparison study. ... AstraZeneca (AZ) has announced that its colorectal cancer drug,

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics